2 - Seminal Abstract
ICON 7: Final overall survival results in teh GCIG phase III randomized trial of bevacizumab in women with newly diagnosed ovarian cancer
Tuesday, March 25, 2014: 9:15 AM
Ballroom B/C (Tampa Convention Center)
A. M. Oza1, T. J. Perren2, A. M. Swart3, W. Schröder4, E. Pujade-Lauraine5, H. Havsteen6, P. J. Beale7, G. Cervantes8, A. C. Embleton9 and M. Parmar10
1University Health Network, Princess Margaret Hospital, Toronto, ON, Canada, 2St James Hospital, St. James’s Institute of Oncology, Leeds, United Kingdom, 3MRC/NCRI (Medical Research Council/National Cancer Research Institute), London, United Kingdom, 4GYNAEKOLOGICUM BREMEN, Bremen, Germany, 5Hopital Hotel Dieu, Paris, France, 6Herlev Hospital, Oncology, Herlev, Denmark, 7Royal Prince Alfred Hospital, Camperdown, Australia, 8Issste Hospital, Mexico City, DF, Mexico, 9Newcastle University, Newcastle, United Kingdom, 10Medical Research Council Clinical Trials, London, England
